SCHEMBL3096503

SCHEMBL3096503

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2ccccc2N)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.45
F2 P00734 8/20 0.43
FADS1 O60427 1/20 0.41
ALDH1A1 P00352 2/20 0.39
MAPT P10636 1/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
CA2 P00918 1/20 0.38
KAT6A Q92794 2/20 0.38
F10 P00742 1/20 0.38
PLG P00747 1/20 0.38
PLAT P00750 1/20 0.38
PRSS1 P07477 1/20 0.38
PRSS2 P07478 1/20 0.38
PRSS3 P35030 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3096098 1.00 LARS1 (0.45) LARS1F2FADS1ALDH1A1MAPT
SCHEMBL3086418 0.92 LARS1 (0.42) LARS1F2MAPTKAT6AF10
SCHEMBL3093678 0.92 LARS1 (0.42) LARS1F2MAPTKAT6AF10
SCHEMBL3096442 0.91 LARS1 (0.42) LARS1F2MAPTMEN1KMT2A
SCHEMBL3097119 0.91 FLT1 (0.43) LARS1F2MAPTMEN1NPC1
SCHEMBL3097539 0.91 LARS1 (0.42) LARS1F2FADS1MAPTMEN1
SCHEMBL3084769 0.91 LARS1 (0.42) LARS1F2MAPTMEN1KMT2A
SCHEMBL3088260 0.91 LARS1 (0.42) LARS1F2FADS1MAPTMEN1
SCHEMBL3096934 0.91 LARS1 (0.42) LARS1F2FADS1ALDH1A1MAPT
SCHEMBL3093418 0.91 FLT1 (0.43) LARS1F2MAPTMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885F2 4128/4885FADS1 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.